To Evaluate the Safety and Immunogenicity of 15-valent HPV Recombinant Vaccine in Chinese People Aged 9-45 Years
Phase 2
Active, not recruiting
- Conditions
- HPV InfectionHPV-Related CarcinomaHPV-Related Intraepithelial NeoplasiaGenital Wart
- Interventions
- Biological: Medium dose for 15-HPV vaccineBiological: High dose for 15-HPV vaccineBiological: PlaceboBiological: 9-HPV vaccine
- First Posted Date
- 2025-01-01
- Last Posted Date
- 2025-02-07
- Lead Sponsor
- Shanghai Bovax Biotechnology Co., Ltd.
- Target Recruit Count
- 330
- Registration Number
- NCT06756269
- Locations
- 🇨🇳
Guangxi Zhuang Autonomous Region Center for Disease Control and Prevention, Nanning, Guangxi, China
A Phase III Study to Evaluate the Efficacy, Immunogenicity and Safety of the 9-valent HPV Vaccine in Chinese Males
Phase 3
Active, not recruiting
- Conditions
- HPV-Related CarcinomaPenile CancerAIN3Genital WartAnal CancerPIN3AIN1PIN2PIN-1AIN2
- Interventions
- Biological: 9-valent Human Papillomavirus (Types 6, 11, 16, 18, 31, 33, 45, 52 and 58) Recombinant Vaccine (Hansenula Polymorpha)Biological: Placebo
- First Posted Date
- 2024-06-20
- Last Posted Date
- 2024-12-12
- Lead Sponsor
- Shanghai Bovax Biotechnology Co., Ltd.
- Target Recruit Count
- 9000
- Registration Number
- NCT06465914
- Locations
- 🇨🇳
Guangxi Zhuang Autonomous Region Center for Disease Control and Prevention, Nanning, Guangxi, China
🇨🇳Hunan Center for Disease Control and Prevention, Changsha, Hunan, China
🇨🇳Shanxi Provincial Disease for Control and Prevention, Taiyuan, Shanxi, China
A Phase I Clinical Trial to Evaluate the Safety of 15-valent HPV Vaccine in Healthy Chinese People Aged 18-45 Years
Phase 1
Active, not recruiting
- Conditions
- Genital WartHPV InfectionHPV-Related CarcinomaHPV-Related Intraepithelial Neoplasia
- Interventions
- First Posted Date
- 2024-06-12
- Last Posted Date
- 2025-01-06
- Lead Sponsor
- Shanghai Bovax Biotechnology Co., Ltd.
- Target Recruit Count
- 72
- Registration Number
- NCT06454175
- Locations
- 🇨🇳
Guangxi Zhuang Autonomous Region Center for Disease Control and Prevention, Guangxi, China
A Phase Ⅲ Study to Evaluate the Efficacy, Immunogenicity, Safety of Quadrivalent HPV Recombinant Vaccine in Chinese Healthy Females
Phase 3
Terminated
- Conditions
- CIN2Vin IIAISCervical CancerVin IVin IIIVain IVain IIIGenital WartCIN1
- Interventions
- Biological: PlaceboBiological: Quadrivalent Human Papillomavirus (Types 6, 11, 16, and 18) Recombinant Vaccine (Hansenula Polymorpha)
- First Posted Date
- 2022-10-18
- Last Posted Date
- 2023-07-21
- Lead Sponsor
- Shanghai Bovax Biotechnology Co., Ltd.
- Target Recruit Count
- 3131
- Registration Number
- NCT05584332
- Locations
- 🇨🇳
Yi M, Liuzhou, Guangxi, China
Evaluate the Safety and Immunogenicity of a 9-valent HPV Vaccine in Chinese Healthy Male Aged 9-45 Year-old
Phase 1
Completed
- Conditions
- Anal CancerPenile CancerPIN-1AIN2PIN-2PIN-3AIN1AIN3Genital Wart
- Interventions
- Biological: Placebo among 9-17 yrsBiological: Placebo among 18-45 yrs
- First Posted Date
- 2022-08-26
- Last Posted Date
- 2024-04-17
- Lead Sponsor
- Shanghai Bovax Biotechnology Co., Ltd.
- Target Recruit Count
- 90
- Registration Number
- NCT05518201
- Locations
- 🇨🇳
Center for Disease Control and Prevention, Mianzhu, Sichuan, China
Immune Persistence After the Whole Vaccination Shcedule With Recombination Quadrivalent HPV Vaccine
Recruiting
- Conditions
- Genital WartCIN1CIN2Cervical Cancer Stage IIaVaginal CancerCIN3HPV Infections
- First Posted Date
- 2022-05-12
- Last Posted Date
- 2024-04-17
- Lead Sponsor
- Shanghai Bovax Biotechnology Co., Ltd.
- Target Recruit Count
- 600
- Registration Number
- NCT05371353
- Locations
- 🇨🇳
Yangchun Center For Disease Prevention And Control, Yangchun, Guangdong, China
🇨🇳Center for Disease Control and Prevention, Mianyang, Sichuan, China
Evaluate the Immunogenicity and Safety of 9-valent HPV Recombinant Vaccine in Chinese Healthy Females
Phase 3
Completed
- Conditions
- Vaginal CancerCIN1CIN3VaIN1Genital WartVIN 1VaIN3CIN2VaIN2VIN 2
- First Posted Date
- 2022-05-12
- Last Posted Date
- 2023-11-24
- Lead Sponsor
- Shanghai Bovax Biotechnology Co., Ltd.
- Target Recruit Count
- 1200
- Registration Number
- NCT05372016
- Locations
- 🇨🇳
Guangxi Zhuang Autonomous Region Center for Disease Control and Prevention, Guangxi, China
Immunogenicity and Safety of Quadrivalent HPV Vaccine in Healthy Chinese Female Subjects Aged 9 to 19 Years
Phase 3
Recruiting
- Conditions
- CIN2Genital WartHPV InfectionsVaginal CancerCervical Cancer Stage IIaCIN1CIN3
- Interventions
- Biological: 3-doses Group among 20-26 yearsBiological: 2-doses Group among 9-14 yearsBiological: 3-doses Group among 9-19 years
- First Posted Date
- 2021-08-30
- Last Posted Date
- 2024-04-17
- Lead Sponsor
- Shanghai Bovax Biotechnology Co., Ltd.
- Target Recruit Count
- 1348
- Registration Number
- NCT05027776
- Locations
- 🇨🇳
Center for Disease Control and Prevention, Mianyang, Sichuan, China
Immunobridging Study of 9-valent Human Papillomavirus Recombinant Vaccine in Chinese Females Aged 9 to 19 Years
Phase 3
Recruiting
- Conditions
- VaIN2VaIN3AISCIN1CIN 3VIN 1Vulvar CancerVaIN1Genital WartCervical Cancer
- Interventions
- Biological: 9-valent HPV vaccine
- First Posted Date
- 2021-05-20
- Last Posted Date
- 2024-04-17
- Lead Sponsor
- Shanghai Bovax Biotechnology Co., Ltd.
- Target Recruit Count
- 1200
- Registration Number
- NCT04895020
- Locations
- 🇨🇳
Huakun Lv, Hangzhou, China
Evaluate the Immunogenicity and Safety of 4-valent and 9-valent HPV Recombinant Vaccine in Chinese Healthy Females
Phase 3
Completed
- Conditions
- Cervical CancerCIN3VaIN1Vaginal CancerCIN1VaIN3Genital WartVIN 1VIN 2VaIN2
- Interventions
- Biological: 4-valent HPV VaccineBiological: GARDASIL®Biological: 9-valent HPV Vaccine
- First Posted Date
- 2020-06-11
- Last Posted Date
- 2022-02-25
- Lead Sponsor
- Shanghai Bovax Biotechnology Co., Ltd.
- Target Recruit Count
- 1680
- Registration Number
- NCT04425291
- Locations
- 🇨🇳
Yangchun Center For Disease Prevention And Control, Yangchun, Guangdong, China
© Copyright 2025. All Rights Reserved by MedPath